Gilead Sciences (GILD) Data Shakes-Up Hep-C Space (VRTX) (IDIX) (ACHN)
Up)
Vertex Pharmaceuticals Incorpor (Nasdaq: VRTX) is moving up 7 percent in pre-open trading Friday following disappointing data from Gilead Sciences, Inc. (Nasdaq: GILD) on its Hep-C treatment, showing viral relapse in first month.
Elsewhere in the Hep-C space, Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) is down 11% and Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is not trading yet.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Elsewhere in the Hep-C space, Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) is down 11% and Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is not trading yet.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- OmniVision (OVTI) Volatility Up on Move Lower
- Facebook (FB) Short Interest Nears Double-Digit Levels
- Celldex Therapeutics (CLDX) Announces 'High Response' CDX-011 Trial Data
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
